What happened to your phony Austrian accent that you had about five years ago before you disappeared ducky Arnold? More spankings for you. I hope you have Aflac. t
Reference: Krishna K, Blazer MA, Wei L, et al. Modified gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer (MPC): A single-institution experience. 2015 Gastrointestinal Cancers Symposium; January 15-17, 2015; San Francisco, CA. Abstract 366.
PartII: the competitor had to reduce dosing to every other week due to toxicity:In the study, the median OS was 8.5 months with nab-paclitaxel plus gemcitabine versus 6.7 months with gemcitabine alone (HR = 0.72; P
Further look at the competitor:Changing the administration schedule for gemcitabine plus nab-paclitaxel (Abraxane) from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer, according to a retrospective study presented at the 2015 GI Cancers Symposium.
The less intense treatment schedule demonstrated a median overall survival (OS) of 11.1 months and a median progression-free survival (PFS) of 4.8 months. Moreover, the change in dosing reduced patient medical costs by $5,500 per month.
“Shifting this treatment to every other week gives the immune system time to recover between chemotherapy sessions and results in less overall toxicity. It also means fewer visits to the infusion center to receive chemotherapy,” study author Tanios Bekaii-Saab, MD, gastrointestinal oncology section chief at The Ohio State University Comprehensive Cancer Center (OSUCCC) – James, said in a statement. “This less-intense, every other week treatment approach seems to be effective in treating our patients with metastatic pancreatic cancer while significantly reducing side effects that impact quality of life.”
The FDA approved the combination regimen of gemcitabine and nab-paclitaxel for the treatment of patients with metastatic pancreatic cancer in September 2013. The approval was based on results from the MPACT trial, which showed that weekly nab-paclitaxel combined with gemcitabine significantly improved both OS and PFS.
In the study, the median OS was 8.5 months with nab-paclitaxel plus gemcitabine versus 6.7 months with gemcitabine alone (HR = 0.72; P
Oncomed to report their ALPINE study results in 2016 for pancreatic CA with two other conventional chemo therapeutic agents of which one is Gemzar:
In the Phase 1b study, tarextumab was administered to standard-of-care chemotherapy to 40 patients with previously untreated, metastatic pancreatic cancer. Thirty-one of the patients received the combination of gemcitabine, Abraxane and tarextumab. Escalating doses of tarextumab were administered every two weeks, ranging from 2.5 mg/kg to 15 mg/kg. Diarrhea, fatigue and anemia were the most common treatment-related toxicities, and the events were mostly Grade 1 or 2, and managed with supportive care. The randomized, double blinded Phase 2 portion of the ALPINE study is currently enrolling patients with first-line advanced pancreatic cancer at 36 clinical sites in the United States. Data are anticipated in the first half of 2016 for both the intent to treat population as well as the tumor Notch3 biomarker positive patients.
Thus there is something good and bad with everything even vicl. t
I would venture to say that if all eight of so of you couldn't afford one squashing seesion because of your poor vicl results that maybe you could all pitch in and receive a treatment together........I think area under the curve would allow that to happen. Just all of you have some restraint and enjoy your drink of choice, our lucky charm, prune after you've received your squashing treatment. Maybe vicl not moving up has been a blessing in disguise for you all becoming better squashing buddies. t
You might hold your favorite drink, prune juice, before a treament session. t
When you sit on Santa's lap at the dept store just tell him that all you want for X-mas is more spankings because that is your future. Maybe you could get some help by joining one of those squashing clubs where the big sits on you squashes you for a price. You would then get treatment and we wouldn't be hearing from you:
You people are really showing your ignorance by trying to make something out of ISIS drug that they sold to BMY being dropped TWO YEARS ago. ISIS had the lead in that drug, in fact it was ISIS that declared that first over any big pharmas in regards to that target. With ISIS new and more powerful screening techniques they discovered how to greatly reduce the injection site reactions, and flu like symptoms that patients were getting. The problem was that this upgraded medicine would be behind that of AMGN's and REGN's AND ISIS has a better more unique prospect where they have the total time advantage, that being their ApoCIII inhibitor. This drug will have three parts to it. First it will be used for patients with FCS. There are only about 3000 patients total with that disease here and in the EU. The FCS patient population usually have triglycerides over a 1000 . They then will have a second indication for patients with triglycerides over 880, and finally a third indication for patients with high triglycerides that aren't responsive to conventional triglyceride lowering therapy. This population could be in the millions. The other drug that ISIS has a huge lead in developing that other copy-cats want in on is their ANGPKL3 inhibitor. Another powerful lipid lowering drug. Just on of these drugs will be worth 20 fold vicl's whole company's worth. The spankings will keep coming and they will be more frequent. The Brown family is looking for some black and blue vicl holders for help in AL right now. t
bcpiii, Would sure like to see how these nanoparticles stack up against the industry standards in that field. I believe that the company has some type of quiet period as I have sent them an email and tried to call IR twice. Listened to their last CC and it was good, not a whole lot of new news but continued moving forward. The amazing thing was that with all of their drugs they continue to have upward dosing in search of the maximum dosing toxicity and one drug I believe is up to 1000mg. Pretty amazing esp. if it holds in regards to what we've seen previously for efficacy. t
There's about six of you and only two Brown daughters there in Alaska.......let the Prune Wars for those two women amongst you six prune eaters begin. t
A lot of jealousy by the whole group. Problem for them is that ISIS will only continue to pull away from vicl and thus the jealous will just get worse. Only cure is for them is to join the Brown family on the Discoery Channel and move to Alaska and stay away from the Internet. They can still buy prune juice there but it will be more expensive......there is no perfect world. t
If you are lucky enough to hold vicl stock certificates they could be very valuable once the company goes BK as brokerage firms no longer let you have stock certificates and there are a number of collectors out there that hold BK company stock certificates as an investment. Like collecting coins. I heard that the CEO was trying to get a market of dog selfies who had oral melanoma with before and after picutures and have those traded on an exchange too.......kind of like a Johnny Bench baseball card for dog selfie mouth picture collectors. Sounds hot, just like the rest of the vicl pipeline. t
Wonder why you are writing for Pee Wee Herman. Coming over to a board that isn't for your investment and offering nothing. I wonder how the CEO of vicl is going to be the boat captain for that cruiserline in Italy and run the vicl company both at the same time.........Maybe he'll run both like the guy he learned from who had that recent accident over there. Make sure like that captain if you own vicl that you have a net that you will "just drop into" like that captain did. Drinking plenty of prune juice on the cruise might help too. Cruising toward the pink sands of Bermuda, or the pink sheets.......you decide. t
MR this is the only thing that ISIS and vicl have in common. That being if you bought vicl as a buyout company you have the wrong company too. It will be demoted to the pink sheets and the equipment will be used to grow prunes. t
Mark your words, what is so big about that? Are you going to send every long here a check for $100 bucks if it doesn't happen? What's all the drama Broadway Joe? Mark your words, like ya. t
So each and every biotech needs to move en-bloc eh? Keep checking in all through April and see if you can make the same statement. t